Creative Biolabs Unveils Its ADCC Enhancement Technology for Oncology Research

New York City, New York Aug 20, 2023 (Issuewire.com) - With an unwavering commitment to empowering global oncology pioneers, Creative Biolabs is revolutionizing therapeutic antibody development by fortifying ADCC activity, offering an extensive array of services for cutting-edge experimental research.

Antibody-dependent cell-mediated cytotoxicity (ADCC) serves as a cornerstone of the immune system, wielding a pivotal role in identifying and eradicating cancer cells. Recognizing the paramount significance of ADCC in modern immunotherapy, Creative Biolabs has harnessed its expertise to construct an inventive platform catering to ADCC/CDC development services.

Armed with top-tier solutions, Creative Biolabs is at the forefront of aiding researchers worldwide in fabricating therapeutic antibodies endowed with heightened ADCC potency, encompassing two integral approaches: therapeutic antibody glycosylation engineering and therapeutic antibody Fc engineering.

Elevating Impact through Antibody Glycosylation Engineering

Exploiting the transformative potential of glycosylation - the attachment of carbohydrate molecules to proteins - Creative Biolabs aids to change the landscape of therapeutic antibodies. The exclusive therapeutic antibody glycosylation engineering service enables precision in tailoring the glycosylation pattern of therapeutic antibodies. This innovative engineering process yields amplified ADCC activity, ultimately amplifying the therapeutic efficacy against malignant cells.

Powered by the GlycoDegree platform, Creative Biolabs excels in generating glyco-engineered antibodies within diverse mammalian and non-mammalian cell systems. The scope of antibody glyco-engineering services encompasses, yet is not limited to:

* Desialylated and Highly Sialylated Antibodies Engineering

* High Mannose Antibodies Engineering

* Homogeneous Glycoforms Engineering

* Fc Silence Engineering

Optimizing Interaction with Antibody Fc Engineering

The Fc region of antibodies triggers the annihilation of target cells by engaging immune cells - a critical process integral to ADCC. Creative Biolabs' therapeutic Fc engineering service is laser-focused on refining this pivotal interaction. Leveraging advanced molecular engineering techniques, the company crafts bespoke Fc regions for therapeutic antibodies to ensure a more robust interaction with immune cells. This refined strategy significantly amplifies ADCC potency, thus elevating the overall efficacy of therapeutic interventions.

This technology spans multiple subfields to cater to diverse research demands, encompassing non-glycosylated Fc modification services and therapeutic antibody Fc modification services designed to inhibit or stimulate effector functions, regulate complement activation, and modulate the half-life of IgG molecules.

Besides, Creative Biolabs also lends support to ADCC/CDC-enhanced antibody development, supplying stable cell lines and enhancing biobetter antibodies.

An expert in therapeutic antibody research at Creative Biolabs affirms, "Backed by cutting-edge equipment and seasoned researchers, Creative Biolabs' ADCC enhancement technology stands poised to equip researchers with tools that have the potential to facilitate the anti-cancer antibody development."

For more information on Creative Biolabs' ADCC enhancement platform, please visit https://adcc.creative-biolabs.com.

About Creative Biolabs

Creative Biolabs is poised to present its distinctive antibody development technology to researchers worldwide at various upcoming exhibitions and summits. Following Creative Biolabs to explore solutions that redefine possibilities in the realm of antibody discovery and development!

Media Contact

Candy Swift

[email protected]

https://adcc.creative-biolabs.com